Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.43 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3230997 | 0.93 | MAPK14 (0.42) | MAPK14GAAMAPTTDP1MAPK13 | |
| SCHEMBL2842940 | 0.85 | MAPK14 (0.43) | MAPK14GAAMAPTTDP1MAPK13 | |
| SCHEMBL2846610 | 0.82 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5104614 | 0.79 | RIPK3 (0.54) | MAPK14GAAMAPTTDP1RIPK3 | |
| SCHEMBL2843548 | 0.77 | MAPK14 (0.63) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5104762 | 0.73 | MAPK14 (0.52) | MAPK14GAAMAPTTDP1MAPK13 | |
| SCHEMBL6509449 | 0.71 | MAPK14 (0.52) | MAPK14MAPTMAPK13MAPK12MAPK11 | |
| SCHEMBL828544 | 0.71 | MAPK14 (0.55) | MAPK14GAAMAPTMAPK13MAPK12 | |
| SCHEMBL5095846 | 0.71 | GAA (0.44) | MAPK14GAAMAPTTDP1 | |
| SCHEMBL5095692 | 0.70 | RIPK3 (0.51) | MAPK14GAAMAPTTDP1MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069436-A1 | IMIDAZOLE COMPOUNDS HAVING AN ANTIINFLAMMATORY EFFECT | Merckle (DE) | 2010-03-18 | — | — | US | disclosed |
| EP-2054404-A1 | IMIDAZOLE COMPOUNDS HAVING AN ANTIINFLAMMATORY EFFECT | MERCKLE GMBH (DE) | 2009-05-06 | — | — | EP | disclosed |
| EP-1894925-A1 | Imidazole compounds having an antiinflammatory effect | MERCKLE GMBH (DE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2008023066-A1 | IMIDAZOLE COMPOUNDS HAVING AN ANTIINFLAMMATORY EFFECT | MERCKLE GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069436-A1 | IMIDAZOLE COMPOUNDS HAVING AN ANTIINFLAMMATORY EFFECT | MIF, TNF, IL1B | MAPK14 2368/4885GAA 3866/4885MAPT 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.